ArticleOncogene2004
'Designer' tumors in mice.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models.Research square · 2023Article
- MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.Oncogene · 2016Review
- How genetically engineered mouse tumor models provide insights into human cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
- Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Lentivirus-mediated oncogene introduction into mammary cells in vivo induces tumors.Neoplasia (New York, N.Y.) · 2008Article
- Experimental models of hepatocellular carcinoma.Journal of hepatology · 2008Review
- Wnt signaling, stem cells, and the cellular origin of breast cancer.Stem cell reviews · 2007Review
- Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Functional consequences of IGFBP excess-lessons from transgenic mice.Pediatric nephrology (Berlin, Germany) · 2005Review
- Transgenic rescue of insulin receptor-deficient mice.The Journal of clinical investigation · 2004Article
- A mouse model of uterine leiomyosarcoma.The American journal of pathology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We have developed and tested successfully a general method based on Cre-mediated recombination that can be used for ubiquitous or tissue-specific expression of protein products, including tumor-inducing oncoproteins. Depending on the specificity of a chosen promoter driving cre expression, tumors develop by design in bitransgenic mouse progeny derived by crossing Cre-producing mice with partners carrying a dormant oncogenic transgene (targeted into the 3' noncoding region of the cytoplasmic beta-actin locus) that becomes functional after excision of a 'floxed' DNA segment. To provide proof-of-principle, we have used as models transgenes encoding the polyomavirus middle T antigen (PVMT) and the T antigens of the SV40 early region (SVER). Cre-dependent activation of widespread SVER expression resulted in hyperplasias or invasive tumors affecting particular visceral smooth muscles, whereas Cre-dependent, mammary gland-specific expression of PVMT-induced adenocarcinomas, according to plan. Unexpectedly, we also encountered spontaneous (Cre-independent) oncogene expression occurring as a rare event, which simulates the initiation of sporadic tumors and leads to PVMT-induced hemangiomas and mammary carcinomas or SVER-induced disseminated sarcomas, thus, revealing particular tissue susceptibilities to the actions of these oncoproteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.